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Summary Rationale: To investigate if systemic steroids influence the antibody
response to the 23-valent pneumococcal polysaccaride vaccine (23-PPV) in COPD
patients.
Patients and methods: COPD patients on: (a)X10mg of prednisolone/day (SS,
n¼ 30); (b) inhalative steroids (IS, n¼ 30); (c) controls without COPD (CG, n¼ 29)
were vaccinated with 23-PPV. The concentration (mg/ml) of capsular specific anti-
pneumococcal IgG antibodies (AB) for the serotypes (PNC) 4,6B,9 V,14,18C,19F,23F
were measured by Elisa technique before, 3 and 12 months (m) after vaccination.
Non-responders were defined when AB-concentrations did neither doubled nor reach
X1 mg/ml.
Results: N¼ 24 (CG), n¼ 29 (IS), n¼ 18 (SS) patients completed the study (mean
age 64 yrs.). Serious adverse events were not observed. Geometric mean (GM) AB-
concentration of all serotypes increased significantly (CG, IS, SS) 3 and 12m after
vaccination (Po0.05). The percentage of non-responders ranged between 16% (PNC
19F, IS) and 65% (PNC 4, SS) after 3m and 21% (PNC 19F, IS) and 82% (PNC 4, CG) after
12m. Neither post-vaccine AB-concentrations (3 and 12m) nor the rate of non-
responders differed significantly between patients on systemic steroids and the
other groups (IS, CG).
Conclusions: Systemic steroids did not influence the AB-response. In all groups
mean AB-concentration increased significantly after vaccination but an important
percentage of subjects of all three groups were non-responders.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
COPD is a major public health problem and in
recent projections COPD will be the third most
frequent cause of death and the fifth cause of
disability-adjusted life years lost worldwide in
2020.1 Streptococcus pneumoniae is one of the
main pathogens causing pulmonary infections in
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this patient group.2 The 23-valent pneumococcal
polysaccharide vaccine (23-PPV) is recommended
for COPD patients by major health authorities in
Europe and the US.3–6 Despite this vaccination rates
and acceptance by physicians varies widely.5,7
Although the 23-PPV seems to be beneficial in large
studies8–10 the results of some publications addres-
sing the effectiveness of the 23-PPV in preventing
pneumococcal community-acquired pneumonia
(CAP) in high risk groups are inconclusive.10–13
The immune response to the polysaccharide
vaccine has been studied in several age groups
and in subjects with co-morbidities. Data suggest
that the protective effect of the pneumococcal
vaccine diminishes with age.10,14 In around 20% of
elderly patients vaccinated with PPV antibody
response and functionality of antibodies are defi-
cient.14,15 So far only few studies have addressed
the issue of the immunogenity of the pneumococcal
vaccine in COPD patients.16–18 In this patient group
systemic steroids are frequently prescribed during
exacerbations and in the treatment of advanced
stages of the disease. To the authors knowledge
there are no data about a possible influence of
systemic steroids, taken by COPD patients, to the
immunogenity of the 23-valent polysaccharide
vaccine. Thus the main objective of the present
study was to examine whether a daily systemic
steroid medication alters the immunogenity of the
23-PPV in this patient group.
Methods
The study period was from July 1999 until Decem-
ber 2001. Patients with COPD (n¼ 60) were
recruited at our 250 bed chest city hospital and
controls at a collaborating internal medicine
doctors office (n¼ 29). The diagnosis of chronic
obstructive bronchitis was made according to Ger-
man and European guidelines.19,20 We excluded
patients previously vaccinated with 23-PPV, sub-
jects under immunosuppressive medication other
than prednisolone, patients with HIV, tuberculosis,
insulin-dependent diabetes, known renal disease or
malignancies. Every included patient fulfilled at
least one criterion for pneumococcal vaccination
according to the recommendations of the German
health authorities.3 All subjects were vaccinated
with 0.5ml of a standard, commercially available
23-PPV (Pneumopurs, Chiron Behring, Marburg,
Germany). Concentration of capsular specific anti-
pneumococcal IgG antibodies for the serotypes
(PNC) 4,6B,9 V,14,18C,19F,23F at baseline, after 3
and 12 months were measured. Written informed
consent was obtained from all subjects prior to
inclusion to the study. The study protocol was
approved by the Ethical Committee of the Medical
Faculty, Free University Berlin.
Definition of groups
(1) COPD patients with a systemic steroid therapy
(SS): All subjects had a history of COPD and
were medicated with 10mg or more of pre-
dnisolone/day (or an equivalent dose of an-
other steroid). Medication and dose had to be
equal or over 10mg/day (maximum 30mg)
prednisolone equivalent for at least 2 weeks
prior to inclusion and had to be taken for at
least 3 weeks after vaccination.
(2) COPD patients on inhalative steroids (IS):
Criteria for inclusion to this group was a
documented history of COPD and a daily
treatment with inhalative steroids (any dose
of beclometasone, budenoside or fluticasone).
(3) Control group (CG): At least one criterion for
pneumococcal vaccination according to the
recommendations of the German health autho-
rities was applicable to all subjects in this
group.[3] Patients with pulmonary co-morbidity
(asthma, COPD, emphysema or bronchiectasis)
were excluded.
Measurement of antibodies
Quantitative measurements of pneumococcal cap-
sule-specific IgG were performed from patients
serum collected before vaccination (1), after 3
months (2) and 12 months (3). Serotype-specific
IgG-antibody concentration (PNC) was measured by
a modified ELISA technique using Nunc CovaLinks
microtiter plates (Nunc, Germany) and serum lot 89-
SF as standard serum (FDA, Bethesda, MD). Serum
samples were preincubated with 10mg/ml pneumo-
coccal polysaccharide C (CPS, Statens Seruminstitut,
Denmark) for blocking of unspecific anti-CPS-anti-
bodies. Reference serum 89-SF kindly provided by
Dr. Frash (Rockville, USA) was used for assay
standardisation. Sera with known high antibody
titers were used as reference and quality control
sera. Minimum antibody detection level was 0.1mg/
ml. Evaluation of the method and specific details
about the proceedings of the Nunc CovaLink NHs
ELISA method have been previously described.21
Performed comparisons and definition of
non-responders
Mean pneumococcal capsule-specific IgG concen-
trations at baseline, 3 and 12 months after
vaccination were compared. Patients were defined
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as non-responders when after vaccination (3 and 12
months) baseline polysaccharide specific AB-con-
centration did neither increase two-fold nor the
increment reached at least X1 mg/ml (absolute).
Patients with high pre-vaccination antibody levels
to the tested serotypes (X4 mg/ml) were excluded
from the analysis of non-responders. Further sub-
jects were categorized in those who did respond (as
previously defined) to less than two or more than
five of the seven tested serotypes.
Statistical analysis
Results of antibody concentrations are expressed as
geometric mean7SD. Multiple comparisons of con-
tinuous variables were done by ANOVA with
Bonferroni post hoc correction. In case of signifi-
cant differences of mean serotype-specific IgG-
antibody concentrations each patient group was
opposed to each other group by an additional test.
Therefore for non paired, continuous variables we
used the Kruskal–Wallis or Mann–Whitney test, for
paired variables the Wilcoxon signed rank test.
Categorical variables were compared using the Chi-
square test or Fisher exact test, when appropriate.
The level of significance was set at Po0.05. Data
analysis was performed with SPSSs version 10 on a
standard personal computer with a Windows oper-
ating system (Windows 98s).
Results
Of 89 initially enrolled patients (CG n¼ 29, IS n¼ 30,
SS n¼ 30) n¼ 71 completed the study (CG n¼ 24, IS
n¼ 29, SS n¼ 18; male 57%, female 43%) over the
period of one year. Mean age in the studied groups
was (SS) 64 yr (710.4, range 45–84yr), (IS) 62yr
(712, 39–81 yr) and (CG) 64 yr (718.5, 24–91 yr),
respectively. Dropout rate was highest in SS (40%,
n¼ 12). 8 patients (27%) in the SS group died during
the study period as a consequence of their advanced
pulmonary disease. 97% (n¼ 29) of IS and 83% (n¼ 24)
of CG-patients completed the study. Dropouts in IS
and CG were due to missed follow up. The mean
prednisolone doses at the moment of vaccination in
the group on systemic steroids were as follows: (a) at
the moment of vaccination 21.177.5mg; (b) 2 weeks
prior to vaccination 17.178.7mg and (c) 3 weeks
after vaccination 13.775.3mg.
Vaccine tolerability
The vaccine was well tolerated. No serious adverse
events were observed. Dropouts due to death were
in no relation to vaccination and occurred at least 3
months after vaccination (range 3–10 months). 16%
of all patients reported local reactions and 5%
fatigue for less than two days. In no case a
physician had to be consulted because of vaccine
related adverse event. Differences in side effects
between the groups were not significant.
Antibody concentrations
Baseline pneumococcal capsule-specific IgG anti-
body concentrations of all tested serogroups
showed no significant differences. Mean antibody
concentrations increased significantly in all groups
3 months and one year after vaccination (Po0.05;
see Table 1 and Fig. 1). Mean PNC 14 concentrations
were significantly higher in (IS) compared to
(CG) after 3 and 12 months (geometric mean
(mg/ml)7SD: 3 months (IS) 10.2740.5 vs. (CG)
4.4737.4, P¼ 0.03; one year (IS) 9.4723 vs. (CG)
3.3722, P¼ 0.01). (SS) showed no significant
differences in mean antibody concentrations after
vaccination when compared to the other groups.
Response to the vaccine varied widely between all
serotypes and all tested groups reflecting the wide
range of antibody concentrations after vaccination
(see Table 1).
Non-responders to vaccination
We found non-responders to vaccination in all
groups and serotypes. The percentage of NR 3
months after vaccination ranged as follows in the
different groups: CG 24% (PNC 18C, n¼ 4) to 53%
(PNC 9V, n¼ 10); IS 16% (PNC 19F, n¼ 3) to 56%
(PNC 18C, n¼ 13); SS 17% (PNC 14, n¼ 2) to 65%
(PNC 4, n¼ 11). After 12 months the percentages of
non-responders increased: from CG 33% (PNC 18C,
n¼ 6) to 82% (PNC 4, n¼ 19); IS 21% (PNC 19F, n¼ 4)
to 67% (PNC 23F, n¼ 16); SS 39% (PNC 14, n¼ 5) to
69% (PNC 23F, n¼ 11) (see Fig. 2).
Analysis revealed the following significant differ-
ences: non-responders to PNC14 were more fre-
quent in the control group when compared to
subjects on inhalative steroids 3 months (47% vs.
17%, Po0.05) and 12 months (60% vs. 22%, Po0.05)
after vaccination. The rate of non-responders to
the tested serotypes in the SS group did not differ
significantly when compared to the other groups
(CG and IS). After 12 months non-responders to
PNC18 were more frequent in patients on inhalative
steroids when compared to controls (65% vs. 33%,
Po0.05).
The percentage of subjects who responded to
less than two serotypes ranged between 14% (CG)
ARTICLE IN PRESS
Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. 1189
and 21% (SS) after 3 months and 28% (both SS and
IS) and 33% (CG) after 12 months. Responders to
more than five serotypes ranged from 21% (SS) to
33% (IS) after 3 months and 17% (CG, SS) and 28%
(IS) after 12 months. Differences were not sig-
nificant (see Table 2).
Discussion
The main findings of our study are: (1) mean
pneumococcal capsule-specific IgG antibodies in-
creased significantly 3 and 12 months after vacci-
nation in all groups; (2) the antibody
concentrations after vaccination showed a high
variability in all groups; (3) the hypothesis that
systemic steroids would alter the immunogenity of
the vaccine was not confirmed under the present
experimental conditions. We observed differences
between COPD-patients under inhalative steroids
and controls, specially as regards PNC14; (4) We
found an important percentage of non-responders
to the seven tested serotypes after one year (21–
83%). Non-responders to less than two serotypes
ranged between 14–21% and 28–33% after 3 months
and one year, respectively.
Previous studies have addressed the issue of
magnitude, duration, quality and function of the
23-PPV. Rubins et al. compared the immunogenity
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Table 1 Geometric mean (GM), standard deviation (SD) and range of anticapsular pneumococcal antibodies of
the tested serotypes (PNC, in mg/ml, m¼months).
CG IS SS
GM SD Range GM SD Range GM SD Range
PNC 4
Baseline 0.6 1.3 0.1–6.6 0.8 1.4 0.1–5 0.6 3.1 0.1–17
3m 2.2 5.6 0.1–18 2.3 5.1 0.3–29 1.1 3.6 0.1–19
12m 1.6 5.6 0.2–25 1.6 2.8 0.3–13 1.2 3 0.1–12
PNC 6B
Baseline 0.9 1.8 0.1–6 1.8 4.4 0.1–24 1.3 2.8 0.1–12
3m 3.1 11.5 0.1–45 4.7 7.6 0.5–40 3.1 22.1 0.1–117
12m 2.3 5 0.1–16 3.7 8 0.1–32 2.8 10.9 0.1–48
PNC 9
Baseline 1.1 1.9 0.1–9.4 1.5 2.1 0.1–8.5 1 2.5 0.1–11
3m 3.1 10.2 0.1–41 4.6 10.4 0.5–50 2.8 11.4 0.1–55
12m 3.1 8.4 0.3–31 3.8 5.3 0.3–21 2.2 3.7 0.1–12
PNC 14
Baseline 1.6 7.9 0.3–43 1.5 1.8 0.1–6.8 1.3 10.9 0.1–56
3m 4.4* 37.5 0.2–145 10.2* 40.5 0.8–193 5 13.2 0.2–63
12m 3.3* 22.2 0.3–87 9.3* 23.1 0.3–87 4.8 9.6 0.1–32
PNC 18C
Baseline 1 1.9 0.1–5.9 1.4 1.9 0.2–8.1 1.3 6.5 0.1–36
3m 5.1 26.5 0.4–136 4.5 9.9 0.5–40 3.9 10.1 0.1–37
12m 3.8 10.5 0.3–37 3.5 8.3 0.2–31.1 2.6 5 0.1–20
PNC 19F
Baseline 2 8.7 0.2–40 2.5 3.6 0.6–13.8 2 3.6 0.1–14
3m 6.9 17.5 0.1–82 9.3 22.3 0.9–105 5.3 11.9 0.1–54
12m 4.4 8.9 0.7–31 7.2 12.3 0.6–43 3.8 5.2 0.1–18
PNC 23F
Baseline 2 8.7 0.2–40 2.5 3.6 0.6–13.8 2 3.6 0.1–14
3m 6.9 17.5 0.1–82 9.3 22.3 0.9–105 5.3 11.9 0.1–54
12m 4.4 8.9 0.7–31 7.2 12.3 0.6–43 3.8 5.2 0.1–18
CG¼ control group (n¼ 29), IS¼ inhalative steroids (n¼ 30), SS¼ systemic steroids (n¼ 30). Mean pneumococcal capsule-
specific IgG did increase significantly after 3 and 12 months in all PNC and all groups (CG,IS,SS). The IS had higher mean PNC 14
concentration when compared to CG (3 and 12 months, Po0.05). Significant differences are marked with ‘‘*’’ (Po0.05).
1190 A. de Roux et al.
of the vaccine (serotypes 2, 6B, 8, 12F, 14, 19A,
19F, 25) in elderly subjects (465 years) and
younger healthy adults (o35 years).15 Both groups
had comparable results as regards pre-vaccination
titers and mean fold-rises of anti-pneumococcal
antibodies 16 months after vaccination. However,
in the elderly, serotype 8 was significantly
lower and serotype 14 induced the highest
antibody response showing an important variability
of the immunogenity of the tested antibodies
in the vaccine. A meta analysis showed high
‘‘antigenicity’’ of the serotypes 8, 3, 9 and 14 in
normal subjects after vaccination.22 Further
serotypes 33F, 15B, 9N and 20 were reported to
be the most immunogenic in elderly adults.23
In our study we found PNC 14 and 19F to
produce the highest immune response. PNC14 was
significantly more immunogenic in COPD patients
on inhalative steroids when compared to
controls. A possible explanation for this finding
can be co-morbidities or co-medications in
the control group. The daily use of an angioten-
sin-converting-enzyme inhibitor for e.g. has been
described to be an independent risk factor
for poor antibody response to the pneumococcal
vaccine.15 In the present study we did not control
the patient groups for non-immunomodulating
medication.
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Figure 1 Geometric mean concentrations (mg/ml) of serotype-specific IgG antibodies to pneumococcal capsular
polysaccharides for seven serotypes (mg/ml). Measurements were performed before, 3 and 12 months after vaccination
with 23-valent PPV. Mean pneumococcal capsule-specific IgG did increase significantly after 3 and 12 months in all PNC
and all groups (CG,JS,SS). Note that PNC 14 and 19F concentrations were higher (different scale). IS had higher mean
PNC 14 concentration when compared to CG (3 and 12 months, Po0.05). Significant differences are marked with ‘‘*’’
(Po0.05).
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As regards mean antibody concentrations we
found no significant differences between COPD
patients on systemic steroids and the other groups.
Despite this in 5 of the 7 tested serotypes (PNC 4,
9 V, 18C, 19F, 23F) mean antibody concentrations of
the systemic steroid group were lower compared to
both other groups. We cannot discharge that if the
dose or duration of the systemic steroid treatment
would have been higher this observation might
have reached significance.
Rubins et al. reported that a significant propor-
tion of the elderly (B20%) were ‘‘poor responders’’
defined as subjects with a less than a twofold
increase of baseline titers in two of seven ser-
otypes. The percentage of elderly with an 42 fold
antibody titer ranged between 70% (PNC 2 after 3
months) and 10% (PNC 25 after 16 months). In the
present study the rate of non-responders to the
tested serotypes ranged between 16–65% after 3
months and 21–82% after one year. Further,
approximately 20% of patients did respond to less
than two of seven serotypes in the vaccine after 3
months. This rate increased to 30% after 12 months.
For the evaluation of pneumococcal vaccination, it
is important to consider the pre-immunization
status and age in the studied patients. In the
present study, there was no significant difference in
the age distribution of groups nor an increased
number of non-responders in the elderly patients
475 years.
The results of previous studies addressing the
immune response after vaccination of COPD pa-
tients are controversial. In an early study Landes-
man et al. reported that antibody levels after
vaccination with the 14-valent PPV induced anti-
body concentrations in elderly COPD patients for
nine of 12 serotypes and concluded that antibody
titers for at least one year after vaccination were
sufficient.17 In COPD patients antibody titers after
vaccination were shown to decline faster when
compared with healthy controls.16 Neither of this
studies did stratify patients according to their
steroid medication. In the present study therapy
with systemic steroids did neither reduce the
immunogenity of the vaccine nor increase the rate
of non-responders.
We recognize some possible limitations of the
present study. First we did not test the opsonphay-
gocytotic activity of the antibodies induced by
the vaccine. Differences in the avidity of anti-
bodies induced by 23-PPV have been strongly
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Figure 2 Percentages of non-responders (Y axis) 3
months (upper figure) and 12 months (lower figure) after
vaccination with the 23-PPV. X axis¼ serotypes tested in
the three groups. Only patients that completed the study
are shown (CG n¼ 24, IS n¼ 29, SS n¼ 18). Patients with
high pre-vaccination antibody levels to the respective
tested serotypes (44mg/ml) were excluded (PNC 4 CG/
SS/IS n¼ 1/1/4, 6B n¼ 5/4/11, 9 n¼ 5/3/7, 14 n¼ 4/7/
5, 18C n¼ 6/6/6, 19F n¼ 6/10/10, 23F n¼ 3/4/5). Non-
responders were defined when after vaccination baseline
polysaccharide specific AB-concentration did neither
increase two-fold nor the increment reached at least
X1 mg/ml. ‘‘*’’ indicates significant differences (Po0.05)
between the groups.
Table 2 Number and percentage of subjects who
responded to either o2 or 45 of the tested 7
serotypes.
CG IS SS
N(%) N(%) N(%)
3m
Response to o2PNC 4(14) 5(17) 6(21)
Response to 45PNC 9(32) 10(33) 6(21)
12m
Response to o2PNC 8(33) 8(28) 5(28)
Response to 45PNC 4(17) 8(28) 3(17)
Response is defined as a twofold increase of baseline
antibody levels or an increase of at least 1mg/ml.
Differences between groups were not significant
(P40.05).
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suggested.14,24 Despite this it is known that
recurrence of pneumococcal pneumonia is related
to a poor antibody response after vaccination with
the 23-valent PPV as described by Hedlund et al.25
Therefore the concentration of IgG specific anti-
bodies reflects the level of protection against
pneumococcal pneumonia.
A further possible limitation is our suggested
definition of non-responders. We created this
specification to identify those patients who respond
poorly to the vaccine. It is frequently stated but not
documented that a normal antibody response to
vaccination should include at least a twofold
increase in antibody titers. Former studies regard-
ing the antibody response to pneumococcal vacci-
nation have used this definition.15,22 We choose the
level of 1 mg/ml absolute increase in antibody
concentration because some pre-vaccination anti-
body titers were very low and a twofold increase in
antibody titers would not have reflected a suffi-
cient (protective) immune response. Therefore we
also did not include subjects with high pre-vaccine
antibody levels (44 mg/ml) in the analysis of non-
responders as those patients have probably a
sufficient AB-concentration to protect them against
invasive pneumococcal disease. Although a protec-
tive antibody concentration has not been estab-
lished most studies show a mean antibody response
after vaccination of 2–10 mg/ml in healthy volun-
teers.14,15,22
We conclude that vaccination of COPD patients
with or without a systemic steroid medication
the 23-valent PPV is safe and produces a significant
increase of mean antibody concentration. There-
fore we agree with current vaccine recommenda-
tions, specially as recent data suggest that patients
clearly benefit from a co-vaccination of the
pneumococcal and influenza vaccine.11 This mea-
sure has been proven to be safe in patients
with chronic respiratory conditions.26 But an
important subset of our patients regardless of
their steroid medication or concomitant COPD
failed to respond sufficiently to the vaccine. If
antibody concentrations neither double nor in-
crease towards at least 1 mg/ml, or even decrease
to pre-immunization levels after one year, a
protection against pneumococcal disease is im-
probable regardless of the functionality of the
antibodies. We are in need for new pneumococcal
vaccines that provide longer-term protection and
efficacy in high-risk groups as COPD patients.
Conjugate vaccines have been proven to induce a
sufficient antibody response in patients who are
genetically incapable of responding to polysacchar-
ide vaccines and might be an alternative.27,28 There
are also promising results in mice and in humans of
a vaccine derived from pneumococcal surface
proteins.29,30
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